Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CL
Climb Bio, Inc. Common Stock
CLYM
Mkt Cap
$564.4M
Volume
882.00K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CL
CLYM
CL
Climb Bio, Inc. Common Stock
CLYM
News
·
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight
Mkt Cap
$626.6M
Volume
882.00K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight
The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.
GlobeNewswire Inc. · Apr 6, 2026
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company, announced that its executive team will participate in three upcoming healthcare and biotech conferences in February and March 2026, including Guggenheim's Emerging Outlook: Biotech Summit, Oppenheimer's 36th Annual Healthcare Life Sciences Conference, and Leerink Global Healthcare Conference. Live webcasts will be available on the company's investor relations website.
GlobeNewswire Inc. · Feb 5, 2026
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Climb Bio granted a non-statutory stock option to a new employee for 120,000 shares at $1.76 per share, vesting over four years with standard stock option terms.
GlobeNewswire Inc. · Nov 25, 2025
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
Climb Bio presented preclinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, and long-term clinical data for budoprutug, an anti-CD19 monoclonal antibody showing potential in primary membranous nephropathy treatment.
GlobeNewswire Inc. · Oct 17, 2025
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
Climb Bio, a clinical-stage biotechnology company, will participate in multiple healthcare investor conferences in September 2025, presenting its pipeline of therapeutics for immune-mediated diseases.
GlobeNewswire Inc. · Aug 25, 2025
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Climb Bio, a clinical-stage biotech company, announced progress in its pipeline, including the initiation of clinical trials for its lead candidate budoprutug in 2025 and the advancement of CLYM116 towards IND-enabling studies. The company also appointed two seasoned biotech leaders to its board of directors.
GlobeNewswire Inc. · May 19, 2025
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Climb Bio, a clinical-stage biotechnology company, announced that it will present data on its lead product candidate, budoprutug, an anti-CD19 monoclonal antibody, at the American Society of Nephrology Kidney Week 2024 conference.
GlobeNewswire Inc. · Oct 11, 2024
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Climb Bio, a clinical-stage biotechnology company, will present and host investor meetings at William Blair's event on transforming autoimmune diseases by targeting CD19. Climb Bio's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
GlobeNewswire Inc. · Oct 4, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CL
CLYM
Climb Bio, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
CLYM
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CLYM yet.
Related Tickers
Earnings